162 related articles for article (PubMed ID: 25887663)
21. HLA-G as an Inhibitor of Immune Responses.
Lin A; Yan WH
Methods Mol Biol; 2016; 1371():3-9. PubMed ID: 26530791
[TBL] [Abstract][Full Text] [Related]
22. Tunneling nanotubes enable intercellular transfer of MHC class I molecules.
Schiller C; Huber JE; Diakopoulos KN; Weiss EH
Hum Immunol; 2013 Apr; 74(4):412-6. PubMed ID: 23228397
[TBL] [Abstract][Full Text] [Related]
23. Intercellular exchanges of membrane patches (trogocytosis) highlight the next level of immune plasticity.
Caumartin J; Lemaoult J; Carosella ED
Transpl Immunol; 2006 Dec; 17(1):20-2. PubMed ID: 17157208
[TBL] [Abstract][Full Text] [Related]
24. Capture of membrane components via trogocytosis occurs in vivo during both dendritic cells and target cells encounter by CD8(+) T cells.
Riond J; Elhmouzi J; Hudrisier D; Gairin JE
Scand J Immunol; 2007 Oct; 66(4):441-50. PubMed ID: 17850589
[TBL] [Abstract][Full Text] [Related]
25. Blocking tumor escape in hematologic malignancies: the anti-PD-1 strategy.
Bryan LJ; Gordon LI
Blood Rev; 2015 Jan; 29(1):25-32. PubMed ID: 25260226
[TBL] [Abstract][Full Text] [Related]
26. HLA-G: An Immune Checkpoint Molecule.
Carosella ED; Rouas-Freiss N; Tronik-Le Roux D; Moreau P; LeMaoult J
Adv Immunol; 2015; 127():33-144. PubMed ID: 26073983
[TBL] [Abstract][Full Text] [Related]
27. MICA triggering signal for NK cell tumor lysis is counteracted by HLA-G1-mediated inhibitory signal.
Menier C; Riteau B; Carosella ED; Rouas-Freiss N
Int J Cancer; 2002 Jul; 100(1):63-70. PubMed ID: 12115588
[TBL] [Abstract][Full Text] [Related]
28. Plasma-dependent, antibody- and Fcγ receptor-mediated translocation of CD8 molecules from T cells to monocytes.
Iwasaki S; Masuda S; Baba T; Tomaru U; Katsumata K; Kasahara M; Ishizu A
Cytometry A; 2011 Jan; 79(1):46-56. PubMed ID: 21182182
[TBL] [Abstract][Full Text] [Related]
29. Antigen-specific transfer of functional programmed death ligand 1 from human APCs onto CD8+ T cells via trogocytosis.
Gary R; Voelkl S; Palmisano R; Ullrich E; Bosch JJ; Mackensen A
J Immunol; 2012 Jan; 188(2):744-52. PubMed ID: 22174448
[TBL] [Abstract][Full Text] [Related]
30. NK cells: innate immunity against hematological malignancies?
Costello RT; Fauriat C; Sivori S; Marcenaro E; Olive D
Trends Immunol; 2004 Jun; 25(6):328-33. PubMed ID: 15145323
[TBL] [Abstract][Full Text] [Related]
31. Ligand binding but undetected functional response of FcR after their capture by T cells via trogocytosis.
Hudrisier D; Clemenceau B; Balor S; Daubeuf S; Magdeleine E; Daëron M; Bruhns P; Vié H
J Immunol; 2009 Nov; 183(10):6102-13. PubMed ID: 19841164
[TBL] [Abstract][Full Text] [Related]
32. Galectins in hematological malignancies.
Giordano M; Croci DO; Rabinovich GA
Curr Opin Hematol; 2013 Jul; 20(4):327-35. PubMed ID: 23695449
[TBL] [Abstract][Full Text] [Related]
33. Expansion of CD4(+) HLA-G(+) T Cell in human pregnancy is impaired in pre-eclampsia.
Hsu P; Santner-Nanan B; Joung S; Peek MJ; Nanan R
Am J Reprod Immunol; 2014 Mar; 71(3):217-28. PubMed ID: 24383466
[TBL] [Abstract][Full Text] [Related]
34. Quantified colocalization reveals heterotypic histocompatibility class I antigen associations on trophoblast cell membranes: relevance for human pregnancy.
Jabeen A; Miranda-Sayago JM; Obara B; Spencer PS; Dealtry GB; Hayrabedyan S; Shaikly V; Laissue PP; Fernández N
Biol Reprod; 2013 Oct; 89(4):94. PubMed ID: 24006284
[TBL] [Abstract][Full Text] [Related]
35. HLA-G1 and HLA-G5 isoforms have an additive effect on NK cytolysis.
Zhang WQ; Xu DP; Liu D; Li YY; Ruan YY; Lin A; Yan WH
Hum Immunol; 2014 Feb; 75(2):182-9. PubMed ID: 24269702
[TBL] [Abstract][Full Text] [Related]
36. The non-classical antigens of HLA-G and HLA-E as diagnostic and prognostic biomarkers and as therapeutic targets in transplantation and tumors.
Seliger B
Clin Transpl; 2013; ():465-72. PubMed ID: 25095542
[TBL] [Abstract][Full Text] [Related]
37. Expression of the non-classical HLA-G antigen in tumor cell lines is extremely restricted.
Poláková K; Russ G
Neoplasma; 2000; 47(6):342-8. PubMed ID: 11263857
[TBL] [Abstract][Full Text] [Related]
38. NK resistance of tumor cells from multiple myeloma and chronic lymphocytic leukemia patients: implication of HLA-G.
Maki G; Hayes GM; Naji A; Tyler T; Carosella ED; Rouas-Freiss N; Gregory SA
Leukemia; 2008 May; 22(5):998-1006. PubMed ID: 18288133
[TBL] [Abstract][Full Text] [Related]
39. Identification and characterization of HLA-class-I-restricted T-cell epitopes in the putative tumor-associated antigens P21-activated serin kinase 2 (PAK2) and cyclin-dependent kinase inhibitor 1A (CDKN1A).
Li G; Hundemer M; Wolfrum S; Ho AD; Goldschmidt H; Witzens-Harig M
Ann Hematol; 2006 Sep; 85(9):583-90. PubMed ID: 16718496
[TBL] [Abstract][Full Text] [Related]
40. Rescuing lymphocytes from HLA-G immunosuppressive effects mediated by the tumor microenvironment.
Wu D; Kuiaste I; Moreau P; Carosella E; Yotnda P
Oncotarget; 2015 Nov; 6(35):37385-97. PubMed ID: 26460949
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
